Problemas relacionados a medicamentos nas síndromes hipertensivas gestacionais.
Introduction: Hypertensive syndromes during pregnancy are frequent and antihypertensive therapy is impacted by physiological changes related to pregnancy, which increases the risk of drug-related problems (DRP). Objective: to characterize the main DRPs and their causes related to antihypertensive th...
Na minha lista:
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | bachelorThesis |
| Idioma: | pt_BR |
| Publicado em: |
Universidade Federal do Rio Grande do Norte
|
| Assuntos: | |
| Endereço do item: | https://repositorio.ufrn.br/handle/123456789/50041 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| Resumo: | Introduction: Hypertensive syndromes during pregnancy are frequent and antihypertensive therapy is impacted by physiological changes related to pregnancy, which increases the risk of drug-related problems (DRP). Objective: to characterize the main DRPs and their causes related to antihypertensive therapy in hospitalized pregnant women. Methods: prospective cohort approved by the institutional Research Ethics Committee. All patients consented to participate. Data collection was carried out at the Januário Cicco Maternity School, in the city of Natal-RN, through daily interviews with 547 patients from the high-risk ward, during the months of August 2019 to August 2021. The descriptive analysis with the Stata software version 13. Results: during the study, 33.6% (184) patients had arterial hypertension, 34.2% (187) had gestational hypertension and 12.8% (70) had preeclampsia. The mean treatment time for patients was 5.6 ± 4.2 days, with approximately 7.4 ± 2.9 medications being used per pregnant woman. The most prescribed antihypertensives were hydralazine 20 mg/mL AMP with 38.3% (374), followed by methyldopa 250 mg WITH 28.9% (282), methyldopa 500 mg WITH 16.3% (159) and nifedipine 20 mg COM 12.2% (119). In the MRP profile, the non-ideal drug treatment of nifedipine 20mg presented 63.4%, followed by methyldopa 500mg, 58.9% and methyldopa 250mg, 57.7%. Hydralazine 20mg/mL presented a distinct profile, with a predominance of adverse events among its DRPs, with 88.9%. Conclusion: Of the antihypertensive drugs analyzed, methyldopa 250mg and nifedipine 20mg stood out for their therapeutic ineffectiveness. Regarding the occurrence of adverse reactions, all analyzed drugs had at least one event. These facts occurred mainly during the first two days of hospitalization. |
|---|